Rechallenge With Immunotherapy for ES‐SCLC: Efficacy and Safety From a Retrospective Propensity Score‐Matched Study
Yuxia Wang, Yunfeng Tong, Yang Pan, Xinyue Li, Hui Li · 2026
Read Rechallenge With Immunotherapy for ES‐SCLC: Efficacy and Safety From a Retrospective Propensity Score‐Matched Study by Yuxia Wang, Yunfeng Tong, Yang Pan, Xinyue Li, Hui Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13589171.txt.
Description
Yuxia Wang and co-authors ask whether giving immune therapy again helps lung cancer patients who already failed it once, in this 2026 study. For extensive-stage small cell lung cancer, immune drugs plus chemotherapy are the standard first treatment, but the cancer usually returns. The team reviewed patients at one Chinese hospital who got a second round of treatment.
After matching like patients, seventy-six who restarted immune therapy were compared with seventy-six who did not. Survival and time without growth were nearly the same in both groups. One warning stood out: never-smokers who restarted seemed to fare worse, though the authors call that signal exploratory. Immune side effects were about twice as common in the restart group. The authors conclude the second try brings no clear survival gain.
Catalog record
| CREATOR | Yuxia Wang, Yunfeng Tong, Yang Pan, Xinyue Li, Hui Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |